Stiborova M - Search Results

1

Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances.

Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, Burda JV, Frei E, Stiborova M. Kizek R, et al. Among authors: stiborova m. Pharmacol Ther. 2012 Jan;133(1):26-39. doi: 10.1016/j.pharmthera.2011.07.006. Epub 2011 Aug 3. Pharmacol Ther. 2012. PMID: 21839775 Review.

2

The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.

Poljaková J, Eckschlager T, Hrabeta J, Hrebacková J, Smutný S, Frei E, Martínek V, Kizek R, Stiborová M. Poljaková J, et al. Among authors: stiborova m. Biochem Pharmacol. 2009 May 1;77(9):1466-79. doi: 10.1016/j.bcp.2009.01.021. Epub 2009 Feb 13. Biochem Pharmacol. 2009. PMID: 19426684

3

Ellipticines as DNA-targeted chemotherapeutics.

Stiborová M, Frei E. Stiborová M, et al. Curr Med Chem. 2014;21(5):575-91. doi: 10.2174/09298673113206660272. Curr Med Chem. 2014. PMID: 24059226 Review.

4

Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.

Stiborova M, Rupertova M, Schmeiser HH, Frei E. Stiborova M, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):13-23. doi: 10.5507/bp.2006.002. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006. PMID: 16936898 Review.

5

Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.

Stiborová M, Poljaková J, Ryslavá H, Dracínský M, Eckschlager T, Frei E. Stiborová M, et al. Int J Cancer. 2007 Jan 15;120(2):243-51. doi: 10.1002/ijc.22247. Int J Cancer. 2007. PMID: 17066455 Free article.

6

DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.

Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hrabeta J, Stiborová M. Poljaková J, et al. Among authors: stiborova m. Cancer Lett. 2007 Jul 18;252(2):270-9. doi: 10.1016/j.canlet.2006.12.037. Epub 2007 Feb 16. Cancer Lett. 2007. PMID: 17306925

7

Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.

Stiborová M, Rupertová M, Aimová D, Ryslavá H, Frei E. Stiborová M, et al. Toxicology. 2007 Jul 1;236(1-2):50-60. doi: 10.1016/j.tox.2007.03.026. Epub 2007 Apr 7. Toxicology. 2007. PMID: 17482743

8

Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.

Martinkova E, Dontenwill M, Frei E, Stiborova M. Martinkova E, et al. Among authors: stiborova m. Neuro Endocrinol Lett. 2009;30 Suppl 1:60-6. Neuro Endocrinol Lett. 2009. PMID: 20027146

9

DNA and histone deacetylases as targets for neuroblastoma treatment.

Stiborová M, Poljaková J, Eckschlager T, Kizek R, Frei E. Stiborová M, et al. Interdiscip Toxicol. 2010 Jun;3(2):47-52. doi: 10.2478/v10102-010-0010-6. Interdiscip Toxicol. 2010. PMID: 21217872 Free PMC article.

10

Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy.

Kotrbová V, Mrázová B, Moserová M, Martínek V, Hodek P, Hudeček J, Frei E, Stiborová M. Kotrbová V, et al. Among authors: stiborova m. Biochem Pharmacol. 2011 Sep 15;82(6):669-80. doi: 10.1016/j.bcp.2011.06.003. Epub 2011 Jun 13. Biochem Pharmacol. 2011. PMID: 21683692

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

289 results

Search Page